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Objectives: To develop an economic analysis of the management of pleural effusions in patients 
with imatinib-resistant/intolerant chronic myelogenous leukemia (CML).
Methods: A cost of treatment analysis was conducted from the US payer perspective, based 
on resource utilization data for 48 patients with dasatinib-related pleural effusions at a large 
US cancer center. Probabilities of various procedures and treatment events were derived from 
published resource use data, supplemented with expert opinion. Cost data was derived from 
median reimbursements for relevant CPT codes for outpatient services and medical literature 
for inpatient services. Sensitivity analyses were conducted for types of procedures used. 
All costs were adjusted to US dollars (2007 rates).
Results: Sixty percent of pleural effusions were managed medically costing $750 per episode. 
Forty percent of pleural effusions were more significant (25% of one lung volume), with 
half of those requiring invasive procedures. Cost of inpatient procedures was $10,616 for chest 
tube and $15,170 with pleural catheter. Cost of outpatient procedures was $713 for ultrasound 
thoracentesis and $4,598 for pleural catheter. The average cost of treating a pleural effusion 
was $2,062 to $2,700 for all severity levels and ∼$6,400 to $9,000 for invasive procedures. 
Key cost drivers were invasive procedures and recurrence.
Conclusion: This economic analysis using actually observed treatment patterns suggests that 
the management of pleural effusion adverse events in CML patients is costly, requires intensive 
resource utilization, and may be an important factor in treatment selection.
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Introduction
Imatinib has revolutionized the treatment of chronic myelogenous leukemia (CML) as 
targeted therapy acting on the abnormal protein Bcr-Abl produced by the Philadelphia 
chromosome. With five-year survival rates of 89% in chronic phase CML (CML-CP), 
imatinib is the first-line standard of care for CML-CP treatment.1 However, some CML 
patients may become resistant to imatinib or do not tolerate imatinib.
Two new drugs targeted for CML, nilotinib and dasatinib, have been developed as 
options for imatinib-resistant and/or -intolerant patients. Although these newer drugs 
are effective in obtaining responses in imatinib-resistant/intolerant CML, their target2 
and adverse event profiles differ.3,4
Pleural effusion is usually a rare drug-related adverse event, typically resulting in 
the need for some type of intervention. Common symptoms of pleural effusion include 
significant cough, fatigue, and dyspnea, which may affect the patient’s quality of life.5 
Risk of effusions exists with all the tyrosine kinase inhibitors (TKIs) currently indicated International Journal of General Medicine 2010:3 32
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for CML (imatinib, dasatinib, and nilotinib), but is most 
commonly seen with dasatinib. Recent data from imatinib-
resistant patients receiving dasatinib at a large cancer center 
show that pleural effusion events occur in up to 35% of 
patients, with risk persisting over time.6 Pleural effusion may 
emerge unexpectedly and as late as 24 months into therapy 
with few predictive factors. These effusions can lead to other 
complications and require additional medical resource use 
beyond the typical routine care.6,7 The interventions may be 
costly and add to the overall economic burden and resource 
use of managing CML patients.
Given the published clinical and resource use details 
provided for pleural effusion management in dasatinib-treated 
patients,6,7 our objective was to develop an economic burden 
analysis of treating pleural effusions in CML patients by apply-
ing costs to the published medical resource utilization rates.
Methods
We developed a literature-based cost-of-treatment analy-
sis to determine the economic burden associated with 
treating pleural effusions in CML patients with imatinib 
resistance/intolerance. The analysis adopted a US third 
party payer/insurer perspective including both inpatient 
and outpatient direct medical costs. The model provides 
cost-of-treatment estimates for managing pleural effusion 
adverse events, from initiation of therapy to two years of 
follow-up. The primary clinical input data were derived 
from the observed medical resource utilization reported for 
48 patients with dasatinib-related pleural effusions at one 
large cancer center.6,7
Table 1 summarizes the treatment patterns and rates 
of resource utilization associated with dasatinib-related 
pleural effusions from MD Anderson Cancer Center:6,7 38% 
received an echocardiogram (ECHO); 71% received a course 
of diuretics; 29% had recurrent effusions; 30% received 
steroids; 19% required a median of 3 (range 1–12) thora-
centesis outpatient procedures (or outpatient pleural catheter 
placement) due to dyspnea grade 3 with median volume 
withdrawn per thoracentesis of 1.5 L [range 0.5–2 L]); 4% 
were managed with inpatient chest tube or pleural catheter 
Table 1 clinical and resource use management of pleural effusions in cML6,7
Severity Reported management of dasatinib pleural effusion
All Levels –  Physician evaluation
–  ECHO (38%); and some CT scans (% not specified)
–    chest X-ray (100%)
–    Dose interruptions in 83% for median of 27 days (range 4–113 days), with more than 
one interruption in 29% for recurrence
–    Dose reduction in 71% (n = 34)
Level 1–2
(up to 25% of one lung volume)
–   All episodes resolved upon
    *dasatinib continuation (28%)
    *loop diuretics (14%)
    *both loop diuretics and discontinuation (55%)
–   A short course of oral prednisone (40 mg/day × 4) was required in 24% of low-grade 
effusion patients, which resulted in disappearance of effusion in 72 hours
–    Invasive procedures in 7% (both level 2)
Level 3
(26%–50% of one lung volume)
–    81% interrupted dasatinib and received loop diuretics (the others continued dasatinib 
due to advanced disease)
–    44% received a short course of oral prednisone
–    Invasive procedures in 25%
Level 4–5
(51 to 75% of one lung volume)
–   All interrupted dasatinib and required invasive procedures for management
Invasive procedures –    19% of all patients with pleural effusions required a median of three thoracenteses 
(range 1–12 thoracenteses per patient due to dyspnea grade 3; median volume 
withdrawn per thoracentesis was 1.5 L [range 0.5–2 L])
–    4% of all patients required placement of chest tube
–    4% of all patients required placement of a Denver peritoneovenous shunt
  –    2% of patients received a pericardial window
Notes: Treatment categorized by level of effusion (not ncI grade) and based on volume of lung involved.International Journal of General Medicine 2010:3 33
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placement; 4% required Denver shunts as inpatients for 
recurrent effusions; and 2% required an inpatient pericardial 
window (for pericardial effusion coexisting with the pleural 
effusion).
Clinical expert input was used only to supplement the 
literature related to assumptions of frequency of office 
visits and chest X-rays. For this economic analysis, we 
assumed all patients would incur two additional physician 
office visits for diagnosis and follow-up of pleural effu-
sion, and that two chest X-rays (one at each visit) would 
be performed. This was done to account for a real-world 
practice pattern that was not reflected in dasatinib pleural 
effusion management at the cancer center, given that the 
patient follow-up visits were protocol driven during the 
study.
Standard costs for relevant CPT codes and median reim-
bursement fees for outpatient procedures and office visits 
were retrieved from the Ingenix National Fee Analyzer.8,9 
The CPT code for placement of a Denver peritoneovenous 
shunt (used for a recurrent effusion) was not available. The 
estimated cost for this procedure was based on the CPT code 
49425, insertion of a peritoneal venous shunt, and added costs 
for associated care: two days of general ward hospital stay, 
and two days of physician inpatient visits.
The cost of inpatient management of pleural effusions 
with chest tube placement and other invasive procedures were 
obtained from the medical literature.10,11 The cost of inpatient 
chest tube placement was $10,616, while an inpatient pleural 
catheter placement was $15,170 based on details provided by 
Putnam and colleagues.10 The cost of an inpatient pericardial 
window was $15,344 based on details provided by Girardi 
and colleagues.11
Drug costs for medical management with diuretics 
(furosemide 40 mg daily for 10 days) and steroids (oral 
prednisone 40 mg daily for four days) were based on 
generic cost data from the Redbook.12 In addition to the 
drug acquisition costs of less than one dollar for a course 
of either generic furosemide or prednisone, we included a 
standard $7 dispensing fee to more accurately reflect the 
true cost of having the medication filled in an outpatient 
pharmacy.
Table 2 lists the CPT code, drug, and literature costs that 
were included in our analysis, along with associated prob-
abilities used in calculating the cost of pleural effusions. 
Table 2 Results of economic analysis presenting average cost for treatment of a pleural effusion in cML
Health care resource use Unit cost per 
events
Number 
of units
Probability Invasive 
procedure 
subgroup 
probabilities
Estimated avg 
cost of treatment 
per CML patient 
across all effusions
Estimated avg cost 
of treatment per 
patient requiring 
invasive procedures
course of diuretics $8 1.29 0.68 1.00 $7 $10
Short course of steroids $8 1.29 0.29 0.58 $3 $6
chest X-ray (2 views; cPT 71020) $100 2.58 1.00 1.00 $258 $258
echO (cPT 93307) $484 1 0.38 1.00 $182 $484
Physician office visits (CPT 99214) $117 2.58 1.00 1.00 $301 $301
Outpatient ultrasound thoracentesis $713 3 0.19 0.75 $406 $1,604
(cPT 32000) or or
Outpatient pleural catheter placement10 $4,598 1 0.19 0.75 $874 $3,449
Inpatient chest tube placement10 $10,616 1 0.04 0.17 $446 $1,805
or or
Inpatient pleural catheter placement10 $15,170 1 0.04 0.17 $637 $2,579
Denver shunt placement* $3,807 1 0.04 0.17 $152 $647
Inpatient pericardial window11 $15,344 1 0.02 0.08 $307 $1,279
Average per patient cost without 
pleural catheter:
$2,062 $6,394
Average per patient cost with 
pleural catheter:
$2,717 $9,013
Notes: costs in US dollars (2007 rates). *cost estimate was based on the cPT code 49425, insertion of peritoneal venous shunt. Assumptions included a two-day length 
of stay in general ward at $725/day and two days of physician inpatient visits (cPT 99222 and cPT 99232). Unit costs: Ingenix for cPT codes,8,9 Putnam and colleagues for 
inpatient chest tube and pleural catheter,10 Girardi and colleagues for inpatient pericardial window,11 and Red Book for drug costs.12International Journal of General Medicine 2010:3 34
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We determined the unit cost per health care resource utilized 
and calculated the average per patient cost of pleural effu-
sion with dasatinib. The average per patient cost of treating 
pleural effusions in this patient population was estimated 
by multiplying the number of units of health care resource 
use consumed by the probability of each event occurring. 
For example, in Table 2 the cost of a course of diuretics 
was estimated at $8. The number of units was assumed to 
be 1.29, taking into account the first occurrence and a 29% 
rate of recurrence of pleural effusion that would require 
additional treatment. The probability that a patient would 
require diuretic therapy was 68%, as based on the literature. 
Therefore, the expected cost of diuretic treatment per patient 
was ∼$7 ($8 cost of drug × 1.29 units × 0.68 probability). 
The expected costs for each health care resource use that 
may have occurred for all patients were calculated, as well 
as the average per patient cost considering all health care 
resources consumed. All grades of pleural effusion were 
considered in our analysis.
Sensitivity analyses were conducted to test the assump-
tions and impact on overall costs. All costs are presented in 
US dollars (2007 rates) to reflect year of clinical/resource 
data reported by the cancer center.
Results
Pleural effusion occurred in 35% of dasatinib-treated 
patients.6,7 Sixty percent of pleural effusions reported at 
the cancer center involved 25% of one lung volume and 
were managed medically including diuretics and steroids.6,7 
Costs for this medically managed group were $750 per 
episode, including physician visits, ECHO, chest X-rays 
and medications.
Forty percent of pleural effusions were more significant, 
involving 26% to 75% of one lung volume, with half of 
those patients requiring invasive procedures. Forty-eight 
percent of all pleural effusions were characterized as NCI 
grade 3 or 4 based on symptoms. Inpatient procedures 
for placement of a chest tube or a pleural catheter had 
estimated costs of $10,616 and $15,170, respectively. The 
cost of invasive outpatient management of pleural effusions 
ranged from $713 for ultrasound thoracentesis to $4,598 for 
placement of a pleural catheter (see Table 2). Other costs of 
invasive procedures ranged from $3,807 for placement of a 
Denver shunt (due to recurrent pleural effusions), to $15,344 
for patients who required a pericardial window (due to 
co-existing pericardial effusion with pleural effusion). Table 2 
summarizes the unit cost per health care resource utilization 
associated with the treatment of pleural effusions.
The average per patient cost for treatment of pleural 
effusion was $2,062. If patients were to have placement 
of a pleural catheter instead of thoracentesis or chest tube 
placement, the average per patient cost would increase to 
$2,717. The average total cost of invasive procedure treat-
ment for patients without a pleural catheter was $6,394; 
this increased to $9,013 in patients with a pleural catheter 
(Table 2).
In sensitivity analyses, alternating assumptions indicated 
that the analysis was robust. Costs of treatment of pleural 
effusions were changed based on Medicare reimbursement 
rates for various CPT codes, instead of median fees for 
private payers. Using Medicare reimbursements, the average 
cost per event decreased by only 6%–12% relative to the 
base case results. Assuming no recurrence of pleural effusion 
reduced total average costs by ∼20%, while placement of a 
pleural catheter instead of repeated thoracentesis or chest 
tube placement increased the cost by ∼30%. Additionally, 
excluding the cost for ultrasound-guided thoracentesis 
would only minimally decrease the average per patient costs 
of treating pleural effusions.
Discussion
This economic analysis based on observed treatment patterns 
suggests that the management of pleural effusions in CML 
requires medical intervention and is costly, particularly for 
those requiring invasive procedures. The total average cost 
per patient across all pleural effusions is about $2,000 to 
$2,700 depending on the type of intervention, while the 
total average cost per patient for those requiring invasive 
procedures is estimated to be $6,400 to $9,000. The rate of 
recurrence of pleural effusions was a major cost driver in 
this analysis. Each successive treatment of recurrent pleural 
effusion adds to the costs of therapy, with increased costs 
due to additional hospital stays, increased laboratory and 
radiology costs, increased personnel costs for procedures, and 
increased pharmacy costs. The rate of recurrence of pleural 
effusion was 29%, based on the real-world rates reported in 
the literature.6
The cost of pleural effusion adverse events should be 
considered in the context of the total cost of treating the CML 
patient, of which the primary driver is currently the drug 
cost of tyrosine kinase inhibitor (TKI) therapy. Considering 
that the cost of the newer TKIs may be $150 per day, the 
cost of pleural effusions alone, averaged across the CML 
population, is not a major cost driver of the total cost of 
care. However, for the physician managing an individual 
patient with a significant pleural effusion requiring inpatient International Journal of General Medicine 2010:3 35
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procedures, the pleural effusion may represent 25% of the 
cost of treating their CML.
Development of pleural effusions with dasatinib poses a 
significant challenge to physicians as the risk persists over 
time, onset is unpredictable, and management may require 
repeat invasive procedures and possible complications.6,7 
For example, twelve percent of dasatinib patients with 
CML-CP experience pleural effusions as late as 24 months 
into treatment.7 Over time, risk of all grade (and grade 3/4) 
pleural effusions increases to 29% (12% grade 3/4) in chronic 
phase and 50% (28% grade 3/4) in accelerated phase. The 
true incidence of dasatinib-related pleural effusions in CML 
patients is not yet known because it is a relatively new treat-
ment. However, the incidence of pleural effusion does differ 
based on the dosing regimen of dasatinib. Recent six-month 
phase III trial data published for the 100 mg daily dose of 
dasatinib in CML-CP patients indicate lower rates of pleural 
effusion than the 140 mg daily dose (7%–10% vs 18%–20%, 
respectively).13
While pleural effusion rates have been reduced with a 
100 mg daily dose of dasatinib, pleural effusion in CML 
remains a significant adverse event regardless of the dose 
and may be a clinically important factor in treatment selec-
tion. A frequent intervention in the management of pleural 
effusion is temporary interruption of therapy, which was 
required in 83% of dasatinib patients with a pleural effusion 
for a median of 27 days, after which the dose was reduced 
in 71%.6,7 Almost one-third of patients required treatment 
interruptions on more than one occasion for recurrent pleural 
effusion; a total of 6% of patients were permanently discon-
tinued from dasatinib for recurrent effusions.7 These patients 
may then be at risk for disease progression while the drug is 
being held or discontinued, and the broader socioeconomic 
cost of not effectively controlling CML during these pleural 
effusion events was not considered in the current analysis.
Potential limitations were addressed when possible 
through conservative approaches to the assumptions and 
conducting sensitivity analyses to assess main drivers of 
cost. While health care resource utilization data were based 
on pleural effusions occurring at one major US cancer center, 
the costs applied to the resources were general reimburse-
ments or literature-based costs and not specific to that cancer 
center. Thus, because patient demographics and treatment 
patterns may differ among institutions, costs of treating 
pleural effusions may also vary. For example, we attempted 
to account for differences in treatment patterns by includ-
ing the cost of both inpatient and outpatient pleural catheter 
placement in the analysis.10 We also used the median fees 
for various outpatient procedures, thus the cost estimates for 
half of the payers could be higher. Additionally, as a sensi-
tivity analysis, a Medicare reimbursement perspective was 
considered and average cost of pleural effusion treatment 
decreased only somewhat, suggesting that regardless of type 
of reimbursement structure, treatment of pleural effusions 
remains costly. The most sensitive cost driver in the analysis 
was the type of invasive procedure selected for managing the 
more significant pleural effusions. If the physician is able 
to anticipate early on that multiple thoracentesis procedures 
will be required for a patient, use of an outpatient pleural 
catheter could reduce total cost of management by up to 30%. 
Finally, due to gaps in the literature and variations in expert 
opinion, our analysis included conservative assumptions for 
additional office visits and X-rays, and did not include the 
cost of platelet transfusions that may be needed to perform 
thoracentesis or the cost of follow-up diagnostics/scans. 
Thus, while we present a conservative analysis, the results 
provide an initial estimate of the costs of treating pleural 
effusions in CML patients.
Conclusions
This economic analysis, based on observed treatment and 
resource use patterns, suggests that the management of 
pleural effusions in CML patients is costly and requires 
intensive resource utilization. Understanding of the clinical 
management and economic burden of treatment-related 
adverse events for patients with CML is essential in an era 
of tightening health care budgets. CML therapies without 
significant risk of pleural effusion may provide cost offsets 
related to adverse event management.
Disclosure
This research was funded by Novartis Pharmaceuticals.
References
  1.  Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients 
receiving imatinib for chronic myeloid leukemia. N Engl J Med. 
2006;355(23):2408–2417.
  2.  Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. 
Second generation inhibitors of BCR-ABL for the treatment of imatinib-
resistant CML. Nature Rev Cancer. 2007;7(5):345–356.
  3.  Bristol-Myers Squibb Company. Sprycel (dasatinib) prescribing 
information. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
  4.  Novartis Pharmaceuticals. Tasigna (nilotinib) prescribing information. 
Florham Park, NJ: Novartis Pharmaceuticals; 2007.
  5.  Koledin M, Duric D, Milovancev A, Bijelovic M, Baros B. Pleural 
effusions of malignant etiology: diagnostics, treatment and quality of 
life. Arch Oncol. 2001;9(1):3–7.
  6.  Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion 
in patients with chronic myelogenous leukemia treated with dasatinib 
after imatinib failure. J Clin Oncol. 2007;25(25):3908–3914.International Journal of General Medicine 2010:3
International Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
A key focus is the elucidation of disease processes and management 
protocols resulting in improved outcomes for the patient.The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
36
Stephens et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  7.  Quintas-Cardama A, Kantarjian HM, Munden R, et al. Pleural effusion 
in patients (pts) with chronic myelogenous leukemia (CML) treated 
with dasatinib after imatinib failure (abstract). ASH Annual Meeting. 
Blood. 2006;1:108(11):2164.
  8.  Ingenix. National Fee Analyzer: Charge data for evaluating fees 
nationally. Eden Prairie, MN: Ingenix; 2006.
  9.  Ingenix. Outpatient billing expert. Eden Prairie, MN: Ingenix; 2006.
10.  Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient manage-
ment of malignant pleural effusion by a chronic indwelling pleural 
catheter. Ann Thorac Surg. 2000;69(2):369–375.
11.  Girardi LN, Ginsberg RJ, Burt ME. Pericardiocentesis and 
intrapericardial sclerosis: effective therapy for malignant pericardial 
effusions. Ann Thorac Surg. 1997;64(5):1422–1427.
12.  Thomson Healthcare. Red Book. Montvale, NJ: Thomson Health-
care; 2008.
13.  Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition 
with dasatinib 100 mg once daily preserves efficacy and improves 
tolerability in imatinib-resistant and -intolerant chronic-phase chronic 
myeloid leukemia. J Clin Oncol. 2008;26(19):3204–3212.